B7-H3 ADCs in small cell lung cancer

The captured search returned 8 Phase 3 trial records across 4 asset groups, all marked Active. The groups are ifinatamab deruxtecan, risvutatug rezetecan, YL201, and MHB088C / QLC5508. MHB088C and the QLC5508; QL2107 entry are grouped together following the asset-identity correction. Original drug labels remain available in the trial details and downloads.

Hover for trial details; click or tap a dot to keep its details open. Counts represent registry records, grouped by asset; the corrected MHB088C / QLC5508 group contains two records.

Trial records

Trial ID	Asset	Phase	Status	Trial
NCT06203210	ifinatamab deruxtecan	3	Active	Ifinatamab Deruxtecan (I-DXd) vs Treatment of Physician's Choice in Relapsed Small Cell Lung Cancer
NCT06498479	risvutatug rezetecan	3	Active	HS-20093 vs Topotecan in Relapsed Small Cell Lung Cancer
NCT06526624	risvutatug rezetecan	3	Active	HS-20093 vs Active Surveillance in LS-SCLC
NCT06612151	YL201	3	Active	YL201 vs Topotecan in Relapsed Small Cell Lung Cancer
NCT06954246	MHB088C / QLC5508	3	Active	MHB088C vs TPC in Relapsed SCLC
NCT07099898	risvutatug rezetecan	3	Active	Risvutatug rezetecan vs Topotecan in Relapsed SCLC
NCT07739758	YL201	3	Active	YL201 + Serplulimab vs Carboplatin + Etoposide + Serplulimab in 1L ES-SCLC
NCT07802821	MHB088C / QLC5508	3	Active	QLC5508 + QL2107 vs Tislelizumab + Chemotherapy in Extensive-stage Small Cell Lung Cancer

Download all 8 captured records →

Download the 8 trial records as CSV · Download JSON

Captured on 7 September 2026. “Active” is the database status, not necessarily recruiting. Drug labels may include combination partners. Source and scientific review is pending.

Coverage note: the broader B7-H3/SCLC search contained 20 records labelled Phase 3, while the explicit Phase 3 query returned these 8. This is a captured search result, not an exhaustive landscape; the filtering discrepancy remains unresolved.